메뉴 건너뛰기




Volumn , Issue OCT, 2010, Pages

CYP2D6 testing to predict response to tamoxifen in women with breast cancer

Author keywords

[No Author keywords available]

Indexed keywords


EID: 84873345845     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/currents.RRN1176     Document Type: Article
Times cited : (11)

References (11)
  • 1
    • 19344364880 scopus 로고    scopus 로고
    • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG), May 14-20 PubMed PMID: 15894097
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 May 14-20;365(9472):1687-717. PubMed PMID: 15894097.
    • (2005) Lancet , vol.365 , Issue.9472 , pp. 1687-1717
  • 2
    • 67749114265 scopus 로고    scopus 로고
    • CYP2D6 and tamoxifen: DNA matters in breast cancer
    • Aug Review. PubMed PMID: 19629072
    • Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009 Aug;9(8):576-86. Review. PubMed PMID: 19629072.
    • (2009) Nat Rev Cancer. , vol.9 , Issue.8 , pp. 576-586
    • Hoskins, J.M.1    Carey, L.A.2    McLeod, H.L.3
  • 3
    • 67651177578 scopus 로고    scopus 로고
    • Genotype-guided tamoxifen therapy: Time to pause for reflection?
    • Aug Review. PubMed PMID: 19647203
    • Lash TL, Lien EA, Sørensen HT, Hamilton-Dutoit S. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol. 2009 Aug;10(8):825-33. Review. PubMed PMID: 19647203.
    • (2009) Lancet Oncol. , vol.10 , Issue.8 , pp. 825-833
    • Lash, T.L.1    Lien, E.A.2    Sørensen, H.T.3    Hamilton-Dutoit, S.4
  • 4
    • 70350752331 scopus 로고    scopus 로고
    • Genetic matters of CYP2D6 in breast cancer: Copy number variations and nucleotide polymorphisms
    • Nov PubMed PMID: 19866496
    • Yu KD, Shao ZM. Genetic matters of CYP2D6 in breast cancer: copy number variations and nucleotide polymorphisms. Nat Rev Cancer. 2009 Nov;9(11):842. PubMed PMID: 19866496.
    • (2009) Nat Rev Cancer. , vol.9 , Issue.11 , pp. 842
    • Yu, K.D.1    Shao, Z.M.2
  • 5
    • 67650874081 scopus 로고    scopus 로고
    • Cancer statistics, 2009
    • Jul-Aug Epub 2009 May 27. PubMed PMID: 19474385
    • Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. Epub 2009 May 27. PubMed PMID: 19474385.
    • (2009) CA Cancer J Clin. , vol.59 , Issue.4 , pp. 225-249
    • Jemal, A.1    Siegel, R.2    Ward, E.3    Hao, Y.4    Xu, J.5    Thun, M.J.6
  • 6
    • 84862299221 scopus 로고    scopus 로고
    • Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
    • (Tufts EPC). Project ID: GEN609. December 8
    • Teruhiko Terasawa T, Dahabreh IJ, Castaldi PD, Trikalinos TA. (Tufts EPC). Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Technology Assessment Report. Project ID: GEN609. December 8, 2009.
    • (2009) Technology Assessment Report
    • Teruhiko Terasawa, T.1    Dahabreh, I.J.2    Castaldi, P.D.3    Trikalinos, T.A.4
  • 7
    • 67650333853 scopus 로고    scopus 로고
    • American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction
    • American Society of Clinical Oncology Jul 1 Epub 2009 May 26. PubMed PMID: 19470930; PubMed Central PMCID: PMC2716943
    • Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM; American Society of Clinical Oncology. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009 Jul 1;27(19):3235-58. Epub 2009 May 26. PubMed PMID: 19470930; PubMed Central PMCID: PMC2716943.
    • (2009) J Clin Oncol. , vol.27 , Issue.19 , pp. 3235-3258
    • Visvanathan, K.1    Chlebowski, R.T.2    Hurley, P.3    Col, N.F.4    Ropka, M.5    Collyar, D.6    Morrow, M.7    Runowicz, C.8    Pritchard, K.I.9    Hagerty, K.10    Arun, B.11    Garber, J.12    Vogel, V.G.13    Wade, J.L.14    Brown, P.15    Cuzick, J.16    Kramer, B.S.17    Lippman, S.M.18
  • 10
    • 76749165728 scopus 로고    scopus 로고
    • Association between CYP2D6 polymorphisms and breast cancer outcomes
    • author reply 517 PubMed PMID: 20145226. Feb 10
    • Lash TL. Association between CYP2D6 polymorphisms and breast cancer outcomes. JAMA. 2010 Feb 10;303(6):516; author reply 517. PubMed PMID: 20145226.
    • (2010) JAMA. , vol.303 , Issue.6 , pp. 516
    • Lash, T.L.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.